Objective
StemBANCC, comprising internationally renowned investigators, is ideally positioned to deliver a unique European biorepository and drug discovery pipeline based upon human induced pluripotent stem cells (hiPSC). This unrivalled opportunity will address the pressing therapeutic need in neurodegeneration, neurodysfunction and diabetes. We have immediate access to richly phenotyped subjects with a wealth of clinical data. Furthermore our cohorts include genetic and genome data, allowing us to carefully select subjects for hiPSC based disease model development. This clinical-genetic stratification is essential to ensure that cellular models display disease and therapy relevant phenotypes. hiPSC reprogramming is undertaken by an internationally respected centre, providing robust, reliable and timely delivery of hiPSCs; ensures the biorepository only houses quality assured hiPSC lines; and reduces unwanted variability in assays. We have leading experts in hiPSC differentiation, providing protocols with over 99% efficiency in producing cortical excitatory neurons and cardiomyocytes, which following up-scaling will meet demands of high throughput assays. StemBANCC will deliver a comprehensive ‘omics’ dataset on over 1500 stem cell lines. This includes cells taken at different lineage stages, after therapeutic challenge, monogenic and complex variants, and with matched isogenic controls. The integration of this network/pathway data will define core etiopathological processes, therapeutic generality, reveal on- and off-target effects, allow candidate therapeutic repositioning and decouple tolerance and toxicity pathways. The large-scale integrated datasets then directly guide the disease specific targeted assays, designed to maximize utility in low and high- through compound screening programs. Assay development undertaken by the StemBANCC proposed central test facility thereby provides the final component of our hiPSC platform for drug discovery, development and safety.
Fields of science
- natural sciencesbiological sciencesneurobiology
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesbasic medicinetoxicology
Call for proposal
IMI-JU-04-2011
See other projects for this call
Coordinator
4070 Basel
Switzerland
See on map
Participants (37)
OX1 2JD Oxford
See on map
82256 FURSTENFELDBRUCK
See on map
WC2R 2LS London
See on map
WC1E 6BT London
See on map
72770 Reutlingen
See on map
31000 Toulouse
See on map
Participation ended
101 Reykjavik
See on map
EH8 9YL Edinburgh
See on map
3400 Hillerod
See on map
B15 2TT Birmingham
See on map
85764 Neuherberg
See on map
10117 Berlin
See on map
23562 Lubeck
See on map
NE1 7RU Newcastle Upon Tyne
See on map
1015 LAUSANNE
See on map
6020 Innsbruck
See on map
1211 Geneve
See on map
75654 Paris
See on map
CB2 1TN Cambridge
See on map
30625 Hannover
See on map
69978 Tel Aviv
See on map
60203 Compiegne Cedex
See on map
581 83 Linkoping
See on map
65205 Wiesbaden
See on map
55218 Ingelheim
See on map
2340 Beerse
See on map
RG21 4FA Basingstoke
See on map
64293 Darmstadt
See on map
2880 Bagsvaerd
See on map
02200 Espoo
See on map
CT13 9NJ Sandwich
See on map
94250 GENTILLY
See on map
Participation ended
W1B 1AL LONDON
See on map
91904 Jerusalem
See on map
151 85 Sodertaelje
See on map
60550 Verneuil En Halatte
See on map
NE1 4EP Newcastle Upon Tyne
See on map